Vericiguat for endothelial dysfunction and CRT response in non-responders: the VERCET prospective observational study
Our findings demonstrate that vericiguat reduces ED and enhances the response to CRT in prior non-responders by significantly lowering inflammatory/oxidative stress markers and ET-1.
Authors
- C. La Marca
- Caterina Carusone
- Ciro Romano (ORCID: https://orcid.org/0000-0002-5807-6601)
- Lorenza Marfella
- Raffaele Marfella (ORCID: https://orcid.org/0000-0003-3960-9270)
- Ludovica Vittoria Marfella
- Maria Luisa Balestrieri (ORCID: https://orcid.org/0000-0001-6001-1789)
- Maria Consiglia Trotta (ORCID: https://orcid.org/0000-0001-9813-5955)
- Francesco Nappo
- Alessandro Landolfi (ORCID: https://orcid.org/0000-0001-8984-9702)
- Celestino Sardu (ORCID: https://orcid.org/0000-0001-5099-3790)
- Domenico Cozzolino (ORCID: https://orcid.org/0000-0003-4968-8160)
- Ausilia Sellitto
- Valerio Giordano
- Joshua Riccio
- C Fumagalli
- Natale Marrazzo
- Mario Volpicelli
- Luca Rinaldi
- Nunzia D’Onofrio
- Marianna Abitabile
- Ferdinando Carlo Sasso
- Domenico Cioffi
Institutions
- University of Campania "Luigi Vanvitelli" (IT)
- Santa Maria Nuova Hospital (IT)
- Hospital Episcopal San Lucas (PR)
- Istituto Neurologico Mediterraneo (IT)
- Consorzio Milano Ricerche (IT)
- University of Campania "Luigi Vanvitelli" (IT)
Publication Details
- Journal
- BMC Medicine
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1186/s12916-026-04747-6
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00